← DPP-4 inhibitors × lipids

TrialDiabetes, obesity & metabolism2017

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).

Chang Ho Ahn et al.PubMed ↗Publisher ↗

  • Gemigliptin added to metformin and glimepiridelooks good hereLower HbA1c level, lower fasting blood sugar, lower total cholesterol.Randomised, small.

What the trial testedrandomised · 2017

Randomised vs placebo added to metformin and glimepiride

Probably lowered HbA1c level

−0.87percentage points−1.09 to −0.64

gemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride

As reported

difference −0.87 %, 95% CI −1.09 to −0.64

Randomised vs placebo added to metformin and glimepiride

Probably lowered fasting blood sugar

−0.93mmol/L−1.50 to −0.35

gemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride

As reported

difference −0.93 mmol/L, 95% CI −1.50 to −0.35 · the paper's word: Fasting plasma glucose level

Randomised vs placebo added to metformin and glimepiride

Probably lowered total cholesterol

−0.21mmol/L−0.38 to −0.03

gemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride

As reported

difference −0.21 mmol/L, 95% CI −0.38 to −0.03

Randomised vs placebo added to metformin and glimepiride

Probably lowered LDL cholesterol

−0.18mmol/L−0.34 to −0.01

gemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride

As reported

difference −0.18 mmol/L, 95% CI −0.34 to −0.01

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

gemigliptin added to metformin and glimepiride
placebo added to metformin and glimepiride

Probably lowered HbA1c level−0.87

Probably lowered fasting blood sugar−0.93

Probably lowered total cholesterol−0.21

randomised

the abstract, start to end

… difference in adjusted mean change -0.87%, 95% confidence interval [CI] …

… significantly reduced with gemigliptin (-0.93 mmol/L, 95% CI -1.50 to …

… group compared with the placebo group (-0.21 mmol/L, 95% CI -0.38 to -0.03 mmol/L for total cholesterol, -0.18 mmol/L, 95% CI -0.34 to …

← favours treatmentfavours comparator →
could be chance
HbA1c levelgemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride
−0.87−1.09 to −0.64
Fasting plasma glucose levelgemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride
−0.93−1.50 to −0.35
Total cholesterolgemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride
−0.21−0.38 to −0.03
LDL cholesterolgemigliptin added to metformin and glimepiride vs placebo added to metformin and glimepiride
−0.18−0.34 to −0.01
MetforminDPP-4 inhibitorsSulfonylureas & glinidesGlycemic controlLipids

DPP-4 inhibitors × lipidshelps?replicated

unlikelylikely
1.000.50 without it

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it

Metformin × lipidshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

9 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28026912